Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy

AIDS

Volumn 18, Issue 1, 2004, Pages 75-79

  Myers, Robert P ^a,b,c   Benhamou, Yves ^a   Bochet, Marie ^a   Thibaulit, Vincent ^a   Mehri, Delphine ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF CALGARY   (Canada)

^c G126 ^*  (Canada)

Author keywords

Adverse event; Depression; Hepatitis C; IFN; Non responder; Relapser; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGETRON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANXIETY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEUROPSYCHIATRY; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS REPLICATION; WEIGHT REDUCTION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 1642465363     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401020-00009     Document Type: Article

References (24)

1. Thomas DL. Hepatitis C and human immunodeficiency virus infection. Hepatology 2002; 36:S201-S209.
2. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
3. Sauleda S, Juarez A, Esteban JI, Altisent C, Ruiz I, Puig L, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001; 34:1035-1040.
4. Landau A, Batisse D, Piketty C, Duong Van Huyen JP, Bloch F, Belec L, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15:2149-2155.
5. Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, et al. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. AIDS 2001; 15:1783-1787.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
8. Hadziyannis SJ, Cheinquet H, Morgan T, Diago M, Jensen DM, Sette H, et al. Peginterferon alfa-2a (40 kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [Abstract]. J Hepatol 2002; 36:3A.
9. Shiffman M. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial [Abstract]. Hepatology 2002; 36:295A.
10. Jacobsen I, Russo MW, Brown RS, Lebovics E, Min A, Esposito S, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers [Abstract]. Gastroenterology 2002; 122:626A.
11. Chung R, Andersen J, Alston B. A randomized, controlled trial of pegylated interferon alpha 2a with RBV vs interferon alpha 2a with RBV for the treatment of chronic hepatitis C in HIV coinfection. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Abstract LB15].
12. Perronne C, Carrat F, Banisadr F, Lunel F, Rosenthal E, Pol S. ANRS HC02 - RIBAVIC: a randomized controlled trial of pegylated interferon a-2b plus ribavirin vs. interferon a-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV co-infected patients [Abstract]. Hepatology 2002; 36:283A.
13. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.
14. Hopkins S, Hennessy M, Lyons F, Mulachy F, Bergin C. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in HIV co-infected patients [Abstract]. Hepatology 2002; 36:231A.
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
16. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
17. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23:585-591.
18. Grassi L, Mondardini D, Pavanati M, Sighinolfi L, Serra A, Ghinelli F. Suicide probability and psychological morbidity secondary to HIV infection: a control study of HIV-seropositive, hepatitis C virus (HCV)-seropositive and HIV/HCV-seronegative injecting drug users. J Affect Disord 2001; 64:195-202.
19. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344:961-966.
20. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207-1211.
21. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′- dideoxynucleosides but enhances inhibitory effects of purl ne 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987; 31:1613-1617.
22. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-1379.
23. Balzarini J, Naesens L, Robins MJ, De Clercq E. Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2, 6-diaminopurine riboside. J Acquired Immune Defic Syndr 1990; 3:1140-1147.
24. Hor R, Deshayes J, Banisadr F, Pol S, Rosenthal E, Perrone C, et al. Concomitant DDI/D4T and interferon (standard or pegylated IFN)/ribavirin treatments may induce a high risk of mitochondrial toxicity in HIV/HCV co-infected patients (ANRS HC02-RIBAVIC study) [Abstract]. Hepatology 2002; 36:283A.